Dioctyl phthalate
Based on 2 publication(s) in Google Scholar
Dioctyl phthalate (DNOP) is a plasticizer. Dioctyl phthalate increases the activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) in the liver, as well as the levels of creatinine and urea in the kidney. Exposure to Dioctyl phthalate disrupts the homeostasis of the intestinal microbial community, increases the abundance of pathogenic bacteria, and reduces the abundance of beneficial bacteria such as Lactobacillus. Dioctyl phthalate induces significant and dose-dependent inflammatory responses in the liver, spleen and kidney of mice.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.40%
- CAS No.: 117-84-0
- 화학식: C24H38O4
- 분자량:390.56
-
보관:
Store at room temperature, keep dry and cool.
In solvent -80°C, 1 year , -20°C, 6 months
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Dioctyl phthalate
More
Biological Activity
Dioctyl phthalate (50-500 mg/kg⋅bw; oral gavage; daily; 12 weeks) induces multi-organ damage (liver, spleen, kidney, ileum) and gut microbiota dysbiosis in aged C57BL/6J male mice, with high-dose exposure causing significant weight loss (P < 0.05), increased liver-to-body weight ratio (P < 0.001), elevated hepatic ALT (P < 0.01) and ALP (P < 0.05) levels, increased splenic weight (P < 0.01), elevated renal creatinine (P < 0.05) levels, and reduced Firmicutes/Bacteroidetes ratio in low-dose mice (P < 0.05).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (4-week-old, male, 18-21 g, SPF-grade)[2]
-
Dosage:50 mg/kg⋅bw; 500 mg/kg⋅bw
-
Administration:daily; 12 weeks
-
Result:Caused sluggishness, lethargy, and decreased vitality in high-dose mice.
Increased body weight compared to controls, with smaller increase in high-dose group than low-dose group (P < 0.01).
Increased liver weight in both low-dose (P > 0.05) and high-dose (P < 0.01) groups compared to controls; increased liver-to-body weight ratio in a dose-dependent manner.
Significantly elevated hepatic ALT (P < 0.01) and ALP (P < 0.001) levels in high-dose group compared to controls.
Significantly increased spleen weight (P < 0.05) and spleen index (P < 0.01) in high-dose group compared to controls, with dose-dependent increases in both parameters.
Significantly elevated creatinine (P < 0.05) levels in high-dose group compared to controls; significantly elevated urea levels (P < 0.05) in both dose groups compared to controls.
Significantly increased serum diamine oxidase (DAO) and D-lactic acid levels in both dose groups compared to controls (P < 0.05).
Decreased Firmicutes relative abundance (50.9% in controls, 44.3% in low-dose, 39% in high-dose) and increased Bacteroidetes abundance (24.8% in controls, 35.9% in low-dose, 38.4% in high-dose) with increasing dose.
Significantly decreased Firmicutes/Bacteroidetes ratio in high-dose group compared to controls (P < 0.05).
-
Animal Model:C57BL/6J (76-week-old, male, 29-40 g, SPF-grade)[2]
-
Dosage:50 mg/kg⋅bw; 500 mg/kg⋅bw
-
Administration:daily; 12 weeks
-
Result:Caused sluggishness, lethargy, decreased vitality, and significant weight loss in high-dose mice compared to controls (P < 0.05).
Increased liver weight in both low-dose (P > 0.05) and high-dose (P < 0.05) groups compared to controls; significantly increased liver-to-body weight ratio only in high-dose group (P < 0.001).
Significantly elevated hepatic ALT (P < 0.01) and ALP (P < 0.05) levels in high-dose group compared to controls.
Significantly increased spleen weight (P < 0.01) and spleen index (P < 0.001) in high-dose group compared to controls, with dose-dependent increases in both parameters.
Significantly elevated creatinine (P < 0.05) and urea (P < 0.05) levels in high-dose group compared to controls.
Significantly increased serum diamine oxidase (DAO) levels in high-dose group compared to controls (P < 0.05); significantly increased D-lactic acid levels in both dose groups compared to controls (P < 0.05).
Decreased Firmicutes relative abundance (61.3% in controls, 36.8% in low-dose, 32.4% in high-dose) and increased Bacteroidetes abundance (28.6% in controls, 37.7% in low-dose, 43.9% in high-dose) with increasing dose.
Significantly decreased Firmicutes/Bacteroidetes ratio in low-dose group compared to controls (P < 0.05).
Chemical Information
-
CAS No. 117-84-0
-
Appearance Liquid (Density: 0.978 g/cm3)
-
분자량 390.56
-
화학식 C24H38O4
-
Color Colorless to light yellow
-
SMILES
O=C(OCCCCCCCC)C1=CC=CC=C1C(OCCCCCCCC)=O
-
Synonyms
DNOP; Di-n-octyl phthalate; Phthalic acid dioctyl ester
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Store at room temperature, keep dry and cool
In solvent -80°C 1 year -20°C 6 months
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Food Chem Toxicol
Integrated network toxicology, molecular docking and transcriptomics reveal the mechanistic role of phthalate esters in metabolic disease pathogenesis. [Abstract]2026 Jan:207:115855. PMID: 41275904 -
Planta Med
Discovery and characterization of panaxatriol as a novel thrombin inhibitor from Panax notoginseng using combination of computational and experimental approach. [Abstract]2024 Aug;90(10):801-809. PMID: 38838717
용액&용해도
DMSO : 100 mg/mL (256.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (276 KB)
-
SDS (702 KB)
- English - EN (702 KB)
- Français - FR (702 KB)
- Deutsch - DE (702 KB)
- Norwegian - NO (702 KB)
- Español - ES (702 KB)
- Swedish - SV (702 KB)
- Italian - IT (702 KB)
- Portuguese - PT (702 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5604 mL | 12.8021 mL | 25.6043 mL | 64.0107 mL |
| 5 mM | 0.5121 mL | 2.5604 mL | 5.1209 mL | 12.8021 mL | |
| 10 mM | 0.2560 mL | 1.2802 mL | 2.5604 mL | 6.4011 mL | |
| 15 mM | 0.1707 mL | 0.8535 mL | 1.7070 mL | 4.2674 mL | |
| 20 mM | 0.1280 mL | 0.6401 mL | 1.2802 mL | 3.2005 mL | |
| 25 mM | 0.1024 mL | 0.5121 mL | 1.0242 mL | 2.5604 mL | |
| 30 mM | 0.0853 mL | 0.4267 mL | 0.8535 mL | 2.1337 mL | |
| 40 mM | 0.0640 mL | 0.3201 mL | 0.6401 mL | 1.6003 mL | |
| 50 mM | 0.0512 mL | 0.2560 mL | 0.5121 mL | 1.2802 mL | |
| 60 mM | 0.0427 mL | 0.2134 mL | 0.4267 mL | 1.0668 mL | |
| 80 mM | 0.0320 mL | 0.1600 mL | 0.3201 mL | 0.8001 mL | |
| 100 mM | 0.0256 mL | 0.1280 mL | 0.2560 mL | 0.6401 mL |
Dioctyl phthalate Related Classifications
Cat. No.: HY-W013755
Powered by Bioz
- Dioctyl phthalate
- 117-84-0
- DNOP
- Di-n-octyl phthalate
- Phthalic acid dioctyl ester
- Biochemical Assay Reagents
- Aminotransferases (Transaminases)
- Phosphatase
- Bacterial
- inflammation
- C57BL/6J male mice
- mouse liver
- mouse kidney
- mouse spleen
- alanine aminotransferase
- alkaline phosphatase
- Firmicutes/Bacteroidetes ratio
- gut microbiota
- ileum
- Inhibitor
- inhibitor
- inhibit